Venture capital group leads private financing in molecular diagnostics firm.
In: Biotech Week, 2004-12-29, S. 712-713
serialPeriodical
Zugriff:
The article informs that Sprout Group has led a $20 million series D private equity financing in XDx Inc., a molecular diagnostics company. Sprout Group invested $7 million in the financing, with the remainder coming from new investors JP Morgan's Bay Area Equity Fund, Integral Capital Partners and Burrill & Company, as well as existing investors Kleiner Perkins Caufield & Byers and TPG Ventures. XDx's AlloMap molecular expression testing is a noninvasive assay based on peripheral blood that detects cardiac allograft rejection. Specifically, the AlloMap molecular expression test measures immune cells in the peripheral blood that cause and respond to cardiac allograft rejection. When used in conjunction with clinical judgment and assessment of graft function, AlloMap molecular expression testing may reduce endomyocardial biopsies and immunosuppression therapy.
Titel: |
Venture capital group leads private financing in molecular diagnostics firm.
|
---|---|
Zeitschrift: | Biotech Week, 2004-12-29, S. 712-713 |
Veröffentlichung: | 2004 |
Medientyp: | serialPeriodical |
ISSN: | 1535-2757 (print) |
Sonstiges: |
|